Tumor exosome-derived miR-9 and miR-181a activate the JAK/STAT pathway by targeting the PIAS3 and SOCS3, thus promoting the expression of eMDSCs and might be providing as novel target for IL-6high breast cancer treatment (67). Here, PIAS3 is linked to breast cancer.